Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.
CYBIN INC. filed a Form D notice reporting a Regulation D exempt offering of options. The filing states a total potential offering amount of $637,404 USD (maximum proceeds from option exercises) and that $0 has been sold to date. The securities are stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The issuer selected Rule 506(b) as the exemption and indicated the offering may last more than one year. The Form D lists two investors in the offering, both non-accredited, and discloses no sales commissions or finders' fees and $0 proposed for payments to named executives or directors.
Point72 affiliates reported holding 1,606,317 common shares of Cybin Inc., representing 7.0% of the outstanding class as of June 30, 2025. The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons; each reports 0 sole voting or dispositive power and 1,606,317 shared voting and dispositive power. The statement clarifies that the shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, and that the filing is not an admission of beneficial ownership for Section 13 purposes. The signee is Jason M. Colombo, as authorized person, dated August 14, 2025.
Cybin Inc. filed a Form 6-K as a foreign private issuer for August 2025. The filing states that two exhibits are incorporated by reference into the company’s existing Form F-10 shelf registration statement. These exhibits are a form of amended and restated convertible note and an omnibus amendment dated August 12, 2025. The document is signed by Chief Executive Officer Doug Drysdale.
Cybin Inc. (CYBN) filed a Form D announcing the completion of a Rule 506(b) private placement. The Ontario-based psychedelic therapeutics company sold $50 million in a mix of debt securities, warrants/options, and underlying shares. The first sale occurred on 30 June 2025 and the offering will not extend beyond one year. All of the targeted amount has been placed, leaving $0 remaining.
Key terms
- Total offering size: $50,000,000
- Securities type: Debt plus equity-linked instruments
- Number of investors: 1 (accredited status not disclosed)
- Sales commissions: $2,670,000 (Joseph Gunnar & Co., LLC)
- Finder’s fees: $0
- Proceeds earmarked for insiders: $0
The issuer declined to disclose revenue or asset size. The financing adds fresh capital without immediate payments to executives or directors and is not tied to a merger or acquisition. The exemption selected (Rule 506(b)) restricts general solicitation and requires sales only to accredited investors or up to 35 non-accredited sophisticated purchasers.